Targeting the Programmed Cell Death-1 Pathway in Genitourinary Tumors: Current Progress and Future Perspectives.

Targeting the Programmed Cell Death-1 Pathway in Genitourinary Tumors: Current Progress and Future Perspectives.

Curr Drug Metab. 2017 May 18;:

Authors: Montironi R, Cheng L, Moch H, Lopez-Beltran A, Scarpelli M, Massari F, Fiorentino M, Ciccarese C, Koch M, Kaimakliotis HZ, Wang L, Pili R, Mann SA

Abstract
Immune checkpoint inhibitors have revolutionized the treatment many malignancies with over a dozen new United States Food and Drug Administration (FDA) approvals in the past six years. Due to the combination of potent treatment success and potentially deadly adverse effects from immune checkpoint inhibitors, gathering prognostic and predictive information about FDA-indicated tumors is prudent. PD-L1 expression is a poor prognostic factor and predictive of better responses from both PD-1 and PD-L1 inhibitors in a variety of tumor types including RCC and urothelial carcinoma. Each FDA-approved PD-1/PD-L1 drug is paired with a PD-L1 immunohistochemistry (IHC) assay. The majority of PD-1/PD-L1 inhibitor clinical trials use proprietary IHC antibodies with undefined validation data. Thus, there is need for improved knowledge and application of PD-1/PD-L1 IHC biomarkers. There is a wealth of recent publications using antibody clones to characterize tumor PD-1/PD-L1 expression profiles. PD-1 is expressed on lymphocytes. PD-L1 is expressed on both tumor cells and immune cells. IHC staining appears in membranous fashion. A cutoff of at least 5% tumor cell PD-L1 staining for positivity has worked for most studies. Caution should be observed when employing tissue microarray techniques. RCC has been the most studied of the genitourinary malignancies for PD-L1 expression. The atezolizumab-approved ICH assay is unique in that only immune cell staining is quantified for the use of this assay in urothelial carcinoma. With familiarity of the current FDA guidelines, published medical literature, and general immunohistochemical considerations, the use of immune checkpoint biomarkers can continue to flourish.

PMID: 28524003 [PubMed - as supplied by publisher]

http://ift.tt/2rCT79U